|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intraoperative cell salvage with autologous transfusion in liver transplantation显示文摘Liver transplant(LT) is the primary treatment for patients with end-stage liver disease. About 25000 LTs are performed annually in the world. The potential for intraoperative bleeding is quite variable. However, massive bleeding is common and requires blood transfusion. Allogeneic blood transfusion has an immunosuppressive effect and an impact on recipient survival, in addition to the risk of transmission of viral infections and transfusion errors, among others.Techniques to prevent excessive bleeding or to use autologous blood have been proposed to minimize the negative effects of allogeneic blood transfusion.Intraoperative reinfusion of autologous blood is possible through previous selfdonation or blood collected during the operation. However, LT does not normally allow autologous transfusion by prior self-donation. Hence, using autologous blood collected intraoperatively is the most feasible option. The use of intraoperative blood salvage autotransfusion(IBSA) minimizes the perioperative use of allogeneic blood, preventing negative transfusion effects without negatively impacting other clinical outcomes. The use of IBSA in patients with cancer is still a matter of debate due to the theoretical risk of reinfusion of tumor cells. However, studies have demonstrated the safety of IBSA in several surgical procedures, including LT for hepatocellular carcinoma. Considering the literature available to date, we can state that IBSA should be routinely used in LT, both in patients with cancer and in patients with benign diseases. | Marcelo A Pinto Marcio F Chedid Leo Sekine Andre P Schmidt Rodrigo P Capra Carolina Prediger Jo?o E Prediger Tomaz JM Grezzana-Filho Cleber RP Kruel | 2019 | World Journal of Gastrointestinal Surgery2019，11，1： | 16 |
| 2 | Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial显示文摘 | William T Cefalu Lawrence A Leiter Kun-Ho Yoon Pablo Arias Leo Niskanen John Xie Dainius A Balis William Canovatchel Gary Meininger | 2013 | The Lancet2013，，： | 3 |
| 3 | The Productivity of Cities 显示文摘 | Svikauskas Leo A | 1975 | Quarterly Journal of Economics1975，89，3： | 1 |
| 4 | Partition coefficients and their uses显示文摘 | LEO A HANSCHA C ELKINS D | 1971 | Chem Rev1971，71，6： | 1 |
| 5 | Applying participatory design and collaboration in digital public services for discovering and redesigning e-Government services显示文摘 | Leo G A Panagiotis S Ioannis A T | 2007 | Government Information Quarterly2007，24，2： | 1 |
| 6 | HER-2 amplification and topoisomerase 11 alpha gene aberration as predictive markers in node - positive breast cancer patients randomly treated either withan anthracycline - based therapy or with eyclophosphamide, methotrexate, and 5 - fluorouracil显示文摘 | Di Leo A Gabcberg D Larsimont D | 2002 | Clinical Cancer Res2002，8，： | 1 |
| 7 | The muhifaceted aspects of ecosystem integrity显示文摘 | De Leo G A Levin S | 1997 | Conservation Ecology1997，1，1： | 1 |
| 8 | Experience of endoscopic ultrasound in staging adenocarcinoma of the cardia显示文摘 | De Manzoni G Pedrazzoni C Di Leo A | 1999 | Eur J Surg Oncol1999，25，： | 1 |
| 9 | Mesenchymal stem cells in tissue engineering 显示文摘 | Leo A J Grande DA | 2006 | Cells Tissues Organs2006，183，3： | 1 |
| 10 | Phase 11显示文摘 | di LEO A GOMEZ HL AZIZ Z | 2008 | J Clin Oncol2008，26，34： | 1 |
| 11 | Signal processing for FMCW SAR显示文摘 | Meta A Hoogeboom P and Leo P L | 2007 | IEEE Transactions on Geoseence and Remote SensiTg2007，45，35： | 1 |
| 12 | HER2:a predictive factor ready to use in the daily management of breast patients显示文摘 | Piccorf MJ Di Leo A Hamilton A | | 0，，： | 1 |
| 13 | An outlook on ovarian cancer and borderline ovarian tumors:focus on genomic and proteomic findings显示文摘 | Tinelli A Vergara D Martignago R Leo G Pisanò M Malvasi A | | 0，，： | 1 |
| 14 | Study of the phase structure of linear polyethylene by means of small-angle X-ray scattering and Raman spectroscopy 显示文摘 | NORBERT S RUFINA G A LEO M | 1995 | Maeromoleeules1995，28，14： | 1 |
| 15 | HER-2 and topoi- somerase llalpha as predictive cancer patients randomly treated with adjuvant CMF or epirubicin plus cyelophosphamide显示文摘 | Di Leo A Larsimont D Gabcberg D | 2001 | Ann Oncol2001，12，： | 1 |
| 16 | Biofilm-dependent airway infections: A role for ambroxol显示文摘 | Cataldi M Sblendorio V Leo A | 2014 | Pulmonary pharmacology & therapeutics2014，28，2： | 1 |
| 17 | A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol 显示文摘 | Fasano T Cefalu A B Di Leo E | 2007 | Arterioscler Thromb Vasc Biol2007，27，3： | 1 |
| 18 | Chromogenic in situ hy-bridization : a practical alternative for fluorescence in situ hybridiza- tion to detect HER-2/neu oncogene amplification in archival breast cancer samples 显示文摘 | Tanner M Gancberg D Di Leo A | 2000 | Am J Pathol2000，157，5： | 1 |
| 19 | The nicotinamide phosphoribosyhransferase: a molecular link between metabolism, inflammation, and cancer 显示文摘 | Galli M Van Gool F Rongvaux A An&is F Leo O | 2010 | Cancer Res2010，70，： | 1 |
| 20 | Final overall surviv- al: fulvestrant 500rag vs 250rag in the randomized CONFIRM trial显示文摘 | Di Leo A Jerusalem G Petruzelka L | 2014 | J Nati Cancer Inst2014，106，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员